# BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

> **NCT06414434** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Michael Wagner, MD** · enrollment: 24 (estimated)

## Conditions studied

- Liposarcoma
- Recurrent Liposarcoma
- Metastatic Liposarcoma
- Unresectable Liposarcoma
- MDM2 Gene Amplification
- Myxoid Liposarcoma
- CIC-Rearranged Sarcoma

## Interventions

- **DRUG:** BTX-A51

## Key facts

- **NCT ID:** NCT06414434
- **Lead sponsor:** Michael Wagner, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414434, "BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06414434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*